Table 2.

Primary and secondary outcomes including in our meta-analysis

Study/Trial name	Treatment /Control group	PFS of 18 months since first dose of Daratumumab	ORR*	VGPR*	CR*	PR*	MR*
Dimopoulo s et al./CANDOR Trial	Treatment group	57 (18.3%)	263 (84.3%)	216 (69%)	89 (28.5%)	55 (17.6%)	23 (7.4%)
	Control group	13 (8%)	115 (74.6%)	75 (49%)	16 (10.4%)	6 (4%)	22 (14.3%)
Spencer, et al./CASTOR trial	Treatment group	188 (74%)	201 (80.1%)	149 (59.3%)	69 (27.4%)	52 (20.7%)	9 (3.6%)
	Control group	24 (9.7%)	148 (59.9%)	68 (27.5%)	23 (9.3%)	80 (32.4%)	20 (8.1%)
Dimopoulo s, et al./POLLUX Trial	Treatment group	203 (71%)	261 (91.2%)	221 (77.2%)	144 (50.3%)	40 (14%)	5 (1.7%)
	Control group	127 (45%)	211 (74.5%)	132 (46.6%)	58 (20.5%)	79 (28%)	26 (9.2%)

*PFS: Progression free span, ORR=overall response rate, VGPR=Very good partial response, CR=Complete response, PR=Partial response, MR=Minimal Response